[go: up one dir, main page]

AR102105A1 - Conjugado radiofarmacéutico - Google Patents

Conjugado radiofarmacéutico

Info

Publication number
AR102105A1
AR102105A1 ARP150103118A ARP150103118A AR102105A1 AR 102105 A1 AR102105 A1 AR 102105A1 AR P150103118 A ARP150103118 A AR P150103118A AR P150103118 A ARP150103118 A AR P150103118A AR 102105 A1 AR102105 A1 AR 102105A1
Authority
AR
Argentina
Prior art keywords
linked
radiopharmaceutical
radionuclide
metabolite
vitro
Prior art date
Application number
ARP150103118A
Other languages
English (en)
Original Assignee
The South African Nuclear Energy Corp Ltd
Univ Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The South African Nuclear Energy Corp Ltd, Univ Cape Town filed Critical The South African Nuclear Energy Corp Ltd
Publication of AR102105A1 publication Critical patent/AR102105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Conjugados radiofarmacéuticos para el uso en métodos mejorados de diagnóstico y tratamiento de cáncer. El conjugado radiofarmacéutico comprende, en secuencia: un metabolito que se dirige a células tumorales, ligado a un agente quelante capaz de contener un radionúclido, ligado a un conector capaz de la unión con un agente EPR in vitro o in vivo; o un agente quelante capaz de contener un radionúclido, ligado a un metabolito que se dirige a células tumorales, ligado a un conector capaz de la unión con un agente EPR in vitro o in vivo. Los conjugados radiofarmacéuticos de la presente proporcionan sistemas de suministro de radionúclidos dirigidos activos y pasivos que pueden ayudar a mejorar la biodistribución y la toxicidad farmacológica de los radiofarmacéuticos usados para el diagnóstico y la terapia de cáncer.
ARP150103118A 2014-09-26 2015-09-28 Conjugado radiofarmacéutico AR102105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417067.4A GB201417067D0 (en) 2014-09-26 2014-09-26 Radiopharmaceutical conjugate

Publications (1)

Publication Number Publication Date
AR102105A1 true AR102105A1 (es) 2017-02-01

Family

ID=51901213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103118A AR102105A1 (es) 2014-09-26 2015-09-28 Conjugado radiofarmacéutico

Country Status (13)

Country Link
US (1) US10874753B2 (es)
EP (2) EP4556029A3 (es)
JP (1) JP6821558B2 (es)
KR (1) KR102276804B1 (es)
CN (1) CN107106709B (es)
AR (1) AR102105A1 (es)
AU (1) AU2015323328B2 (es)
CA (1) CA2962525C (es)
GB (1) GB201417067D0 (es)
MX (1) MX385544B (es)
RU (1) RU2017114360A (es)
WO (1) WO2016046793A2 (es)
ZA (1) ZA201702638B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11378564B2 (en) 2014-02-05 2022-07-05 Vyripharm Enterprises, Llc Systems and methods for integrated and comprehensive management of cannabis products
CN105999308B (zh) * 2016-06-29 2020-08-07 华中科技大学同济医学院附属协和医院 一种肿瘤靶向性mri造影剂及其制备方法
CN106377527B (zh) * 2016-09-05 2019-02-26 郑州大学 开链吡啶羧酸衍生物H2dedpa在抗菌领域的应用
US11357873B2 (en) 2016-09-19 2022-06-14 The Hong Kong Polytechnic University Chiral cyclen compounds and their uses
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
IL313115A (en) 2017-05-05 2024-07-01 Centre For Probe Dev And Commercialization R1–IGF monoclonal antibodies and their use
US11191854B2 (en) 2017-05-05 2021-12-07 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
PE20200866A1 (es) * 2017-07-18 2020-08-31 Vyripharm Entpr Llc Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
SG11202004906QA (en) * 2017-12-18 2020-07-29 Janssen Biotech Inc Radiolabeling of polypeptides
MX380340B (es) 2018-03-14 2025-03-11 Instituto Nac De Investigaciones Nucleares 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
WO2019211843A1 (en) * 2018-04-30 2019-11-07 Bar-Ilan University Polymeric core-shell particles
US12194111B2 (en) * 2018-10-16 2025-01-14 Nant Holdings Ip, Llc Alpha emitter compositions and methods
US20210395281A1 (en) * 2020-01-10 2021-12-23 Fusion Pharmaceuticals Inc. Macrocyclic chelates and uses thereof
WO2022032353A1 (en) * 2020-08-14 2022-02-17 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, uses thereof, and methods for the production thereof
CN114949267A (zh) * 2021-03-18 2022-08-30 米度（南京）生物技术有限公司 药物缀合物及其应用
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
WO2022251516A2 (en) * 2021-05-26 2022-12-01 Cornell University Complexes with acyclic chelators and their use in targeted radiotherapy of cancer
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Eczacibaşi Monrol Nükleer Ürünler Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
JPWO2024181576A1 (es) * 2023-03-02 2024-09-06
WO2024245407A1 (en) * 2023-05-31 2024-12-05 Full-Life Technologies Hk Limited Conjugates and uses thereof
CN121398836A (zh) * 2023-06-26 2026-01-23 阿尔布内克斯特有限责任公司 激活glp-1/gip/胰高血糖素受体的白蛋白结合的大分子三重激动剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
AU593611B2 (en) 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
FI923350A7 (fi) * 1991-07-26 1993-01-27 Hoechst Ag Menetelmä aineiden merkitsemiseksi teknetiumilla tai reniumilla
WO1994017829A1 (en) 1993-02-02 1994-08-18 Neorx Corporation Directed biodistribution of small molecules
US6908903B1 (en) * 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US20040067196A1 (en) * 2000-10-11 2004-04-08 Brunke Karen J. Targeted therapeutic lipid constructs
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
CA2455598A1 (en) 2001-07-27 2003-02-13 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
ATE435035T1 (de) 2003-01-13 2009-07-15 Bracco Imaging Spa Verbesserte linker für radiopharmazeutische verbindungen
CN102989018A (zh) * 2005-08-03 2013-03-27 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CA2631784A1 (en) 2005-11-29 2007-06-07 Mallinckrodt Inc. Bifunctional metal chelating conjugates
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2007121453A2 (en) * 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
CN101516899B (zh) 2006-04-19 2016-07-06 得克萨斯大学体系董事会 细胞成像和治疗的组合物和方法
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20100179303A1 (en) * 2007-04-27 2010-07-15 The Regents Of The University Of California Site-specific conjugation of ligands to nanoparticles
CN101333259A (zh) * 2008-07-31 2008-12-31 江苏省原子医学研究所 肝受体显像剂99mTc－半乳糖基化人血清白蛋白融合干扰素的制备及其应用
US8440167B2 (en) 2008-10-27 2013-05-14 University Of Virginia Patent Foundation Multimodal imaging of atherosclerotic plaque targeted to LOX-1
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010062381A1 (en) 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
US9701694B2 (en) 2008-12-02 2017-07-11 The University Of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
KR101055700B1 (ko) * 2009-01-28 2011-08-11 서울대학교산학협력단 면역세포 영상화 및 탐지를 위한 양기능성킬레이트제와 만노실 인혈청알부민의 결합체 및 그의 방사성동위원소 표지 화합물
WO2011008985A2 (en) 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
CN102858794A (zh) * 2009-07-15 2013-01-02 加州大学董事会 细胞内吸收可控制的肽
GB201019118D0 (en) 2010-11-11 2010-12-29 King S College Conjugates and their uses in molecular imaging
US9283279B2 (en) * 2011-05-11 2016-03-15 Ramot At Tel-Aviv University Ltd. Targeted polymeric conjugates and uses thereof
AU2012296937B2 (en) * 2011-08-17 2017-10-12 Merck & Cie Folate conjugates of albumin-binding entities
PL228735B1 (pl) 2012-02-27 2018-04-30 Inst Immunologii I Terapii Doswiadczalnej Pan Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku
TW201511774A (zh) * 2013-09-18 2015-04-01 Iner Aec Executive Yuan 放射性標誌之主動標靶性醫藥組合物及其用途
KR101477498B1 (ko) * 2014-02-21 2014-12-30 고려대학교 산학협력단 죽상동맥경화 영상화용 조성물 및 이를 이용한 죽상동맥경화 진단방법

Also Published As

Publication number Publication date
RU2017114360A3 (es) 2019-04-04
EP3197504A2 (en) 2017-08-02
JP6821558B2 (ja) 2021-01-27
CA2962525A1 (en) 2016-03-31
CN107106709A (zh) 2017-08-29
ZA201702638B (en) 2021-08-25
MX385544B (es) 2025-03-18
AU2015323328A1 (en) 2017-05-04
EP4556029A3 (en) 2025-08-06
CN107106709B (zh) 2021-04-06
WO2016046793A3 (en) 2016-06-09
KR102276804B1 (ko) 2021-07-15
EP4556029A2 (en) 2025-05-21
AU2015323328B2 (en) 2021-02-25
KR20170095810A (ko) 2017-08-23
US20170296684A1 (en) 2017-10-19
BR112017005985A2 (pt) 2017-12-19
GB201417067D0 (en) 2014-11-12
JP2017530131A (ja) 2017-10-12
WO2016046793A2 (en) 2016-03-31
US10874753B2 (en) 2020-12-29
MX2017003886A (es) 2018-01-12
RU2017114360A (ru) 2018-10-26
CA2962525C (en) 2022-08-30

Similar Documents

Publication Publication Date Title
AR102105A1 (es) Conjugado radiofarmacéutico
PH12016500656B1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX343405B (es) Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
BR112018005899A2 (pt) composto e composição farmacêutica
CL2015003285A1 (es) Arilquinazolinas
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2019008028A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
MX2021009222A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
AR110942A1 (es) Composiciones y métodos para terapias de células t con car
EP4212181A3 (en) Methylene carbamate linkers for use with targeted-drug conjugates
UA86448U (ru) Способ получения вещества с потенциальными физиологическими особенностями 1,1'-(2"-бром-2"-хлоретенил)-бис-(5-нитроурацил)

Legal Events

Date Code Title Description
FB Suspension of granting procedure